The Philippines would start its study on “mixing” COVID-19 brands by June and is now waiting for approval from the Food and Drug Administration and the Health Research Ethics Board, the Department of Science and Technology (DOST) said on Monday, May 24.
It will run for 18 months with 1,200 participants involved and will be lead by the Philippine Society for Allergy, Asthma, and Immunology.
The DOST Secretary explained that the trial participants would receive two different brands of vaccines. He also stated that the study will concentrate on combining Sinovac with other brands because the country has a consistent supply of this vaccine.
If proven effective, mixing vaccine brands would benefit the Philippines, where vaccine supplies are currently not evenly distributed among brands.